<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; amendment</title>
	<atom:link href="http://www.tapanray.in/tag/amendment/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Opioid Crisis: A Looming Threat To India?</title>
		<link>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=opioid-crisis-a-looming-threat-to-india</link>
		<comments>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/#comments</comments>
		<pubDate>Mon, 16 Sep 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Atypical]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[epidemic]]></category>
		<category><![CDATA[flip side]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[narcotics]]></category>
		<category><![CDATA[Nexus]]></category>
		<category><![CDATA[Opioid]]></category>
		<category><![CDATA[pain]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[tryst]]></category>
		<category><![CDATA[United States]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9712</guid>
		<description><![CDATA[A serious, but a typical health crisis that has shaken America, is now, apparently, in search of its prey in India – a soft target to ignite a raging fire of misuse or abuse of prescription drugs of addictive in &#8230; <a href="http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/opioid-crisis-a-looming-threat-to-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>OTC Drugs in India: ‘Where Art Thou?’</title>
		<link>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=otc-drugs-in-india-where-art-thou</link>
		<comments>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/#comments</comments>
		<pubDate>Mon, 02 Sep 2019 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advertisement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[classification]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[illegal]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[juggernaut]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[non-prescription]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[rule]]></category>
		<category><![CDATA[schedule K]]></category>
		<category><![CDATA[self-medication]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US_FDA]]></category>
		<category><![CDATA[Where Art Thou]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9692</guid>
		<description><![CDATA[It is now a widely accepted fact that responsible self-medication plays an important role in health care, facilitating greater access to medicines and reducing overall health care cost. With continued improvement in people&#8217;s education, general knowledge and socioeconomic conditions, self-medication has &#8230; <a href="http://www.tapanray.in/otc-drugs-in-india-where-art-thou/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/otc-drugs-in-india-where-art-thou/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical Trials: Critical Need To Improve Patient Participation With Informed Consent</title>
		<link>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent</link>
		<comments>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/#comments</comments>
		<pubDate>Mon, 18 Apr 2016 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[consent]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[II]]></category>
		<category><![CDATA[III]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[informed]]></category>
		<category><![CDATA[IV]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[naive]]></category>
		<category><![CDATA[participation]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[phase I]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[Trial]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7600</guid>
		<description><![CDATA[On April 13, 2016, an article in the Wall Street Journal (WSJ) titled, “Clinical Trials Need More Subjects” underscored an important point that the rate at which the clinical researchers are able to recruit and retain patients for ‘Clinical Trials &#8230; <a href="http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/clinical-trials-critical-need-to-improve-patient-participation-with-informed-consent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EU-FTA, TRIPS-Plus provisions, Data Exclusivity, Public Interest and India</title>
		<link>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india</link>
		<comments>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/#comments</comments>
		<pubDate>Sun, 30 Jan 2011 11:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[EUFTA]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interest. and]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=308</guid>
		<description><![CDATA[Business Standard in its January 27, 2011 edition reported, “Data Exclusivity still key hurdle to India-EU FTA” Before deliberating on this important issue of “Free Trade Agreement (FTA)”, let me touch upon very briefly, for the benefit of all concerned, &#8230; <a href="http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amendment of &#8216;Professional Conduct, Etiquette and Ethics&#8217; Regulations for the Doctors by the MCI could dramatically change the Pharmaceutical Marketing Practices in India, hereafter.</title>
		<link>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter</link>
		<comments>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/#comments</comments>
		<pubDate>Mon, 11 Jan 2010 01:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dramatically]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[Etiquette]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[hereafter]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Professional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=485</guid>
		<description><![CDATA[As reported in the media, the notification of the Medical Council of India (MCI) dated December 10, 2009 amending the &#8220;Indian Medical Council (Professional Conduct, Etiquette and Ethics), Regulations 2002&#8243; has been welcomed by the medical profession. Areas of stricter &#8230; <a href="http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
